Olympus (OCPNY) Stock Price, News & Analysis

Company Overview

Olympus Corporation is a Japan-based medical technology company focused on developing and manufacturing diagnostic and therapeutic solutions for healthcare providers. Its portfolio includes endoscopic systems, surgical visualization equipment, energy devices, and other instruments used in minimally invasive procedures.

The company’s products support a range of medical specialties, including gastrointestinal, respiratory, urology, and general surgery. Olympus is particularly known for its flexible and gastrointestinal endoscopy technologies, which help physicians detect, diagnose, and treat disease while reducing the need for more invasive procedures.

Founded in 1919, Olympus originally built its business around optical products, including cameras and lenses. In 2021, it completed the sale of its camera business to focus exclusively on medical technology. The company serves hospitals, clinics, and healthcare professionals worldwide and is headquartered in Tokyo, Japan. Stefan Kaufmann serves as Olympus’ president and chief executive officer.

Key Stats

• Today's Range: $18.00 to $18.00
• 50-Day Range: $18.00 to $18.00
• 52-Week Range: $16.80 to $74.99
• Volume: 400 shs
• Average Volume: 860,265 shs
• Market Capitalization: $23.15 billion
• P/E Ratio: 21.95
• Dividend Yield: 0.44%
• Price Target: N/A
• Consensus Rating: Buy

Olympus Stock Analysis - MarketRank™

Olympus scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Olympus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Olympus has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -47.27%

Earnings Growth

Earnings for Olympus are expected to decrease by -47.27% in the coming year, from $1.65 to $0.87 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Olympus is 21.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Olympus is 21.95, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.29.

Price to Earnings Growth Ratio

Olympus has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Olympus has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OCPNY.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Olympus has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Olympus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Olympus is 9.76%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Olympus will have a dividend payout ratio of 9.20% next year. This indicates that Olympus will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Olympus this week, compared to 5 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Olympus insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.03% of the stock of Olympus is held by institutions.

Company Calendar

• Last Earnings: 8/05/2021
• Today: 10/11/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OCPNY
• CIK: N/A
• Web: www.olympus-global.com
• Phone: (133) 340-2111
• Fax: 813-3340-2062
• Employees: 31,557
• Year Founded: 1919

Profitability

• EPS (Trailing Twelve Months): $0.82
• Trailing P/E Ratio: 21.95
• Forward P/E Ratio: 10.91
• P/E Growth: 1.07
• Net Income: $1.03 billion
• Net Margins: 13.80%
• Pretax Margin: N/A
• Return on Equity: 24.30%
• Return on Assets: 9.30%

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 1.99
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $7.74 billion
• Price / Sales: 2.99
• Cash Flow: $1.22 per share
• Price / Cash Flow: 14.76
• Book Value: $3.50 per share
• Price / Book: 5.14

Miscellaneous

• Outstanding Shares: 1,285,890,000
• Free Float: N/A
• Market Cap: $23.15 billion
• Optionable: Not Optionable
• Beta: 0.70